Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for December 13th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 13th:

Hibbett Sports, Inc. (HIBB - Free Report) : This athletic-inspired fashion products retailer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 11.9% over the last 60 days.             

Hibbett Sports’ shares gained 5.7% over the last one month above the S&P 500’s increase 1.6%. The company possesses a Momentum Score of A.

Unique Fabricating, Inc. (UFAB - Free Report) : This company that engineers and manufactures multi-material foam, rubber, and plastic components has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.

Unique Fabricating’s shares gained 26.1% over the last one month. The company possesses a Momentum Score of A.

Stitch Fix, Inc. (SFIX - Free Report) : This company that sells a range of apparel, shoes, and accessories has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.

Stitch Fix’s shares gained 23.2% over the last one month. The company possesses a Momentum Score of A.

Ooma, Inc. (OOMA - Free Report) : This company that creates connected experiences for businesses and consumers has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 66.7% over the last 60 days.

Ooma, Inc. Price and Consensus

Ooma, Inc. Price and Consensus

Ooma, Inc. price-consensus-chart | Ooma, Inc. Quote

Ooma shares gained 12.9% over the last one month. The company possesses a Momentum Score of A.

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>